Comment: SXC, Catalyst deal likely to avoid FTC second request on heels of Express Scripts, Medco approval
Pharmacy benefit manager SXC Health Solutions’ decision to buy rival Catalyst Health Solutions for $3.64 billion will likely gain U.S. regulatory approval for boosting competition among smaller firms operating within what...To view the full article, register now.
Already a subscriber? Click here to view full article